Filtered By:
Source: European Heart Journal
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies
Conclusion Urgent surgery was not superior to FT at restoring valve function, but substantially reduced the occurrence of thrombo-embolic events, major bleeding, and recurrent PVT. In experienced centres, urgent surgery should probably be preferred over FT for treating left-sided PVT, pending the results of randomized controlled trials.
Source: European Heart Journal - June 1, 2013 Category: Cardiology Authors: Karthikeyan, G., Senguttuvan, N. B., Joseph, J., Devasenapathy, N., Bahl, V. K., Airan, B. Tags: Valvular heart disease Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischaemic events, including significant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke. Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Udell, J. A., Bonaca, M. P., Collet, J.-P., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S.-J., Montalescot, G., Sabatine, M. S., Braunwald, E., Bhatt, D. L. Tags: Coronary artery disease Source Type: research

Genetic predisposition to smoking in relation to 14 cardiovascular diseases
ConclusionThis MR study supports a causal association between smoking and a broad range of CVDs, in particular, coronary artery disease, heart failure, abdominal aortic aneurysm, ischaemic stroke, transient ischaemic attack, peripheral arterial disease, and arterial hypertension.
Source: European Heart Journal - April 16, 2020 Category: Cardiology Source Type: research

Management of venous thrombo-embolism: an update
Venous thrombo-embolism is the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Recently published landmark trials paved the way for significant progress in the management of the disease and provided the evidence for the ESC Pulmonary Embolism (PE) Guidelines 2014 update. Risk stratification strategies for non-high-risk PE continue to evolve, with an increasing emphasis on clinical prediction rules and right ventricular (RV) assessment on computed tomographic pulmonary angiography. In the field of anticoagulation treatment, pharmacogenetic testing for vitamin K antagonists on top of...
Source: European Heart Journal - November 1, 2014 Category: Cardiology Authors: Konstantinides, S., Torbicki, A. Tags: Frontiers in cardiovascular medicine Source Type: research

CardioPulse Articles * Andreas Gruntzig's beginnings started in peripheral arteries * Developments in the treatment of aortic aneurysms in 2014 * Interventional treatment of venous thromboembolism * From academia to industry * Working in industry requires wanting to make medicines * STEMI and stroke: distant cousins at best
Source: European Heart Journal - March 7, 2015 Category: Cardiology Tags: CardioPulse Source Type: research

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
Conclusions In the present trial, characterized by low event rates, we did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation. However, the results of the trial must be considered in view of its premature termination and lower than expected event rates. The trial is registered with ClinicalTrials.gov, Identifier: NCT00661206.
Source: European Heart Journal - May 21, 2015 Category: Cardiology Authors: Schulz-Schupke, S., Byrne, R. A., ten Berg, J. M., Neumann, F.-J., Han, Y., Adriaenssens, T., Tolg, R., Seyfarth, M., Maeng, M., Zrenner, B., Jacobshagen, C., Mudra, H., von Hodenberg, E., Wohrle, J., Angiolillo, D. J., von Merzljak, B., Rifatov, N., Kufn Tags: Thrombosis and antithrombotic therapy Source Type: research

Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Conclusion In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Magnani, G., Storey, R. F., Steg, G., Bhatt, D. L., Cohen, M., Kuder, J., Im, K., Aylward, P., Ardissino, D., Isaza, D., Parkhomenko, A., Goudev, A. R., Dellborg, M., Kontny, F., Corbalan, R., Medina, F., Jensen, E. C., Held, P., Braunwald, E., Sabatine, Tags: Thrombosis and antithrombotic therapy Source Type: research

Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme
Conclusion In two independent everyday-life cohorts, pre-hospital morphine use in STEMI patients was not associated with worse in-hospital complications and 1-year mortality. Clinical trial registration Clinicaltrials.gov identifier: NCT00673036 (FAST-MI 2005); NCT01237418 (FAST-MI 2010).
Source: European Heart Journal - March 31, 2016 Category: Cardiology Authors: Puymirat, E., Lamhaut, L., Bonnet, N., Aissaoui, N., Henry, P., Cayla, G., Cattan, S., Steg, G., Mock, L., Ducrocq, G., Goldstein, P., Schiele, F., Bonnefoy-Cudraz, E., Simon, T., Danchin, N. Tags: Acute coronary syndromes Source Type: research

Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study)
Conclusion</div>For patients with ACS caused by plaque erosion, conservative treatment with anti-thrombotic therapy without stenting may be an option.</span>
Source: European Heart Journal - August 29, 2016 Category: Cardiology Source Type: research

Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium
Conclusion</div>Ticagrelor, but not CAM, reduces expression and activity of TF and PAI-1 in LAA endocardial cells isolated from patients with AF, indicating possible local antithrombotic effects. Such pleiotropic properties of ticagrelor may contribute to a reduction in thromboembolic complications in patients with AF.</span>
Source: European Heart Journal - January 8, 2017 Category: Cardiology Source Type: research

Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry
ConclusionThe factors predicting adverse events after cardiac catheterization in adolescents and adults with CHD are different than in the general population. Validation of this model in other national or multi-institutional datasets is the next step.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
ConclusionAt one year, clinical outcomes with the SYNTAX-II strategy were associated with improved clinical results compared to the PCI performed in comparable patients from the original SYNTAX-I trial. Longer term follow-up is awaited and a randomized clinical trial with contemporary CABG is warranted.ClinicalTrials.gov IdentifierNCT02015832
Source: European Heart Journal - August 26, 2017 Category: Cardiology Source Type: research

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
ConclusionCompared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.
Source: European Heart Journal - April 13, 2018 Category: Cardiology Source Type: research